Jump To


  • Generic Name: daridorexant tablets
  • Brand Name: Quviviq
Last updated on MDtodate: 10/10/2022


The following are discussed in detail in other sections of the labeling:

  • CNS-Depressant Effects and Daytime Impairment
  • Worsening of Depression/Suicidal Ideation
  • Sleep Paralysis, Hypnagogic/Hypnopompic Hallucinations, and Cataplexy-like Symptoms
  • Complex Sleep Behaviors
  • Patients with Compromised Respiratory Function

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.

The safety of QUVIVIQ was evaluated in three placebo-controlled clinical studies (two 3-month studies of identical design [Study 1 and Study 2], and a 9-month extension study [Study 3]). Study 1 evaluated 50 mg and 25 mg doses of QUVIVIQ, while Study 2 evaluated a 25 mg dose and a 10 mg dose of QUVIVIQ. The 10 mg dose is not an approved dose. A total of 1232 patients (including approximately 40% elderly patients [> 65 years old]), received QUVIVIQ 50 mg (N = 308); 25 mg (N = 618); or 10 mg (an unapproved dose) (N = 306). A total of 576 patients were treated with QUVIVIQ for at least 6 months and 331 for at least 12 months.

Most Common Adverse Reactions

The most common reported adverse reaction (in at least 5% of patients and greater than placebo) during double-blind treatment in Study 1 was headache.

Table 1 shows adverse reactions that occurred in at least 2% of patients treated with QUVIVIQ and more frequently than in patients who received placebo in Study 1.

Table 1 : Adverse Reactions Reported in ≥ 2% of QUVIVIQ-treated Patients and Greater than in Placebo-treated Patients in a 3-Month Placebo-Controlled Study (Study 1)

(N=310) %
(N=308) %
(N=309) %
Nervous System Disorders
Headache* 6 7 5
Somnolence or fatigue* 6 5 4
Dizziness* 2 3 2
Gastro-intestinal disorders
Nausea* 0 3 2
*The following terms were combined:
Headache includes: headache, tension headache, migraine, migraine with aura, head discomfort
Somnolence or fatigue includes: somnolence, sedation, fatigue, hypersomnia, lethargy
Dizziness includes: dizziness, vertigo, labyrinthitis
Nausea includes: nausea, vomiting, procedural nausea


Other Adverse Reactions Observed During Clinical Trials (Study 1 And Study 2)

Other adverse reactions of < 2% frequency but greater than placebo are shown below. The following do not include adverse reactions 1) for which a drug cause was remote, 2) that were so general as to be uninformative, or 3) that were not considered to have clinically significant implications.

  • Sleep paralysis was reported in 0.5% and 0.3% of patients receiving QUVIVIQ 25 mg and 50 mg, respectively, compared to no reports for placebo.
  • Hypnagogic and hypnopompic hallucinations were reported in 0.6% of patients receiving QUVIVIQ 25 mg compared to no cases with QUVIVIQ 50 mg or placebo.



Read Next Article

PHP Code Snippets Powered By : XYZScripts.com